Equity Research
Company-level stock analysis, valuation, margins, balance sheet risk, and rating rationale.

Company-level stock analysis, valuation, margins, balance sheet risk, and rating rationale.
Post-publication reviews that check what happened after earlier Buy and Sell calls.
Daily filing-change notes comparing new 10-K language with prior-year disclosures.
Friday performance updates for the public LF0 research track record.
Franklin Templeton (BEN)’s MD&A section changed the most among 5 companies that filed 10-Ks on 9 November 2026, each compared against its prior-year filing.
Across 235 articles, our hit rate is 80.2% and our average signal return is 22.4%, so the overall record is still solid this run. Among the tiers with meaningful sample sizes, Sell is performing best on both accuracy and average signal return, while
Fair Isaac (FICO) 2026 10-K analysis comparing the 6 November 2026 filing with its prior-year 10-K, highlighting the Business section’s biggest changes.
Rainmaker Worldwide (RAKR)’s Risk Factors section changed the most among 4 companies that filed 10-Ks on 5 November 2026, each compared against its prior-year…
Waitlist
More detailed equity research, scorecards, and performance analysis are coming. Add your email to be first in line.